Global law firm Clifford Chance is advising Charme Capital Partners, a pan-European private equity firm, on the envisaged acquisition of Centogene GmbH, a rare diseases company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients.
The proposed transaction is the result of an extensive strategic alternatives review process announced by Centogene in February 2024. The proposed transaction is expected to close in the first quarter of 2025, subject to the satisfaction or waiver of certain conditions.
The Clifford Chance deal team is led by Jan-Hendrik Horsmeier and Stephanie Horowitz and the core deal team furthermore consists of Robin Traas, Nancy Stoke, Robert Bulte and Martijn van Beusekom. The wider team consists of Dirk Berendsen (Corporate M&A), Sanne Blankestijn, Hannah van Dijk (Employment), Jurre Jurriëns (Antitrust) in Amsterdam, Jörg Rhiel, Paul Kohlhaas, Friedrich von Bülow (Corporate M&A), Dominik Engl, Lukas Panhans, Jule Geiger (Tax), Michael Kümmel (Tech//Digital), Stefan Sax, Philip Rosak (Global Financial Markets) and Amrei Fuder (Real Estate) in Frankfurt, Leonie Sophia Gebauer (Tax) in Munich, Simon Wattenberg (Corporate M&A) and Nicolas Hohn-Hein (Litigation & Dispute Resolution) in Düsseldorf, John Healy (Corporate M&A) and John McManmon (Global Financial Markets) in New York, Megan Gordon, Holly Bauer, David Harris (Litigation & Dispute Resolution) in Washington, and Daniel Royle, Selman Ansari and Elsir Tawfik (Corporate M&A) in Riyadh.
